Self Study - Module 1: TGCT Diagnosis and Referral
September 21, 2020
The accreditation for this activity has expired.
John A. Abraham, MD, FAAOS, FACS
Founder and Chief Emeritus
Division of Orthopaedic Oncology
Rothman Institute
Director of Orthopaedic Oncology
Bone and Sarcoma Oncology
Fox Chase Cancer Center at Temple University Hospital
Philadelphia, PA
Dr John A. Abraham is the founder and chief emeritus of the Orthopaedic Oncology Service at the Rothman Institute in Philadelphia, Pennsylvania. He graduated magna cum laude from Harvard University, and then went on to graduate with high honors from Yale School of Medicine, where he was inducted into the Alpha Omega Alpha Honor Society. While at Yale, Dr Abraham received the prestigious Nicholas Giarman Award for Cancer Research. He then returned to Harvard to complete an orthopedic surgery residency, where he was selected as the Administrative Chief Resident for 2 consecutive terms. He went on to pursue his orthopedic oncology fellowship at Harvard, based at Massachusetts General Hospital and Children’s Hospital Boston.
Dr Abraham was then elected to the faculty of the Dana-Farber Cancer Center, one of the leading sarcoma centers in the world, where he served as primary orthopedic oncologist for 5 years. Dr Abraham was then recruited to the Rothman Institute to develop a world-class sarcoma and orthopedic oncology center. He developed this program from the ground up and then served as the Director of the Jefferson Musculoskeletal Oncology Center at the Kimmel Cancer Center and Chief of the Rothman Institute Orthopaedic Oncology Service for nearly 10 years, during which time he was an Associate Professor of Orthopaedic Surgery and Radiation Oncology at Thomas Jefferson University. He is currently the Director of Orthopaedic Oncology at the Fox Chase Cancer Center, one of the few National Cancer Institute-designated Comprehensive Cancer Centers in the region, and the Director of Orthopaedic Oncology at the Capital Health Medical System in New Jersey.
Dr Abraham is a nationally recognized orthopaedic oncology surgeon and has 15 years of experience in dealing with bone and soft tissue sarcomas and metastatic cancer to the skeleton. He has published numerous scientific articles and book chapters and has been invited to lecture both nationally and internationally on sarcoma, with a particular research interest in difficult pelvis sarcoma problems and revision acetabular joint reconstruction. Dr Abraham has been named a Top Doctor by Philadelphia Magazine for the past 10 years and is named in the America’s Best Doctors list, along with numerous other accolades and honors. He is a member of the Musculoskeletal Tumor Society and the Connective Tissue Oncology Society and is a Fellow of the American Academy of Orthopaedic Surgeons and the American College of Surgeons.
Kristin M. Strogus, PA-C
Physician Assistant
Department of Surgical Oncology
Fox Chase Cancer Center
Philadelphia, PA
Kristin M. Strogus is a surgical oncology physician assistant at the Fox Chase Cancer Center in Philadelphia, Pennsylvania. She received her undergraduate degree in athletic training from West Chester University in West Chester, Pennsylvania, her Master of Arts in Teaching degree from Montclair State University in Upper Montclair, New Jersey, and her Master of Science in Physician Assistant Studies from Philadelphia University (now Thomas Jefferson University East Falls) in Philadelphia.
Ms Strogus worked as an athletic trainer at the collegiate level for 5 years before becoming a physician assistant. After graduation, she spent a year as a hospitalist in inpatient medicine. She then participated in establishing the Orthopaedic Oncology Service at Rothman Institute/Thomas Jefferson University Hospital for 6 years. Ms Strogus currently contributes to building the Orthopaedic Oncology Service at Fox Chase Cancer Center, while also serving as a surgical oncology physician assistant at the Fox Chase Cancer Center East Norriton location. She is also a guest lecturer at Thomas Jefferson University, with a focus on bone and soft-tissue neoplasms, septic arthritis, and osteomyelitis.
Ms Strogus is a member of the American Academy of Physician Assistants, Pennsylvania Society of Physician Assistants, and the Association of Physician Assistants in Oncology. She has presented posters at meetings of the Musculoskeletal Tumor Society.
William D. Tap, MD
Chief Medical Oncologist
Sarcoma Medical Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Dr William D. Tap is a medical oncologist who specializes in treating patients with soft-tissue and bone sarcomas. He received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. Dr Tap went on to complete an internal medicine residency at Vanderbilt University in Nashville, Tennessee, and a medical oncology/hematology fellowship at the University of California at Los Angeles. He is board certified in medical oncology.
Dr Tap is Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center in New York, New York, one of the top hospitals for cancer care in the nation. In addition to his clinical practice, he is involved in clinical trials evaluating the use of emerging anticancer treatments. He has a strong focus on laboratory research, striving to better understand the genetic origins of sarcoma.
Dr Tap has been published more than 100 times, including articles in The New England Journal of Medicine, the Journal of Clinical Oncology, the American Journal of Surgical Pathology, the Journal of the American Medical Association Oncology, and The Lancet Oncology. He has been recognized by New York Magazine as a Top Doctor several times since 2015.
PROGRAM TITLE
Advances in the Multidisciplinary Care of Patients With Tenosynovial Giant Cell Tumor: Self Study
SPONSORSHIP & SUPPORT
This educational activity is Jointly provided by the American Academy of CME, Inc. and Spire Learning.
PROGRAM OVERVIEW
Successful management of individuals with tenosynovial giant cell tumor (TGCT) requires an accurate and timely diagnosis and an understanding of how best to balance benefits and risks when creating individualized treatment plans. Given the absence of practice standards, the complexity of disease management, and the rarity of disease occurrence, members of the care team who may encounter and care for patients with TGCT will benefit from obtaining clinical insights from experts and from having opportunities to build mentoring and collaborative relationships with other clinicians providing care to individuals with this rare tumor.
TARGET AUDIENCE
Medical oncologists, orthopedic oncologists, orthopedic surgeons, radiation oncologists, radiologists, pathologists, oncology nurses, oncology physician assistants, and oncology nurse practitioners
LEARNING OBJECTIVES
Upon successful completion of the activity, learners should be better able to:
- IDENTIFY individuals with TGCT and refer to or partner with tertiary care centers for multidisciplinary management
- DESCRIBE the benefits and risks of available treatment options for localized and diffuse TGCT
- CREATE a collaborative, individualized TGCT treatment plan for a patient with TGCT
ACCREDITATION, CREDIT DESIGNATION, AND DISCLAIMER STATEMENTS
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and Spire Learning. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians: American Academy of CME, Inc., designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners/Nurses: American Academy of CME, Inc., designates this educational activity for 2.0 ANCC contact hours (0.9 pharmacotherapeutic contact hours).
California
Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 2.0 contact hours.
INSTRUCTIONS ON HOW TO RECEIVE CREDIT
There is no fee to participate in this activity. In order to receive CME/CE credit, you must complete:
- Baseline Assessment
- Modules 1, 2, and 3
- Final Assessment
- Activity Evaluation
Your certificate can be printed immediately.
CONFLICT OF INTEREST STATEMENT
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.
FACULTY CO-CHAIRS
John A. Abraham, MD, FAAOS, FACS
Founder and Chief Emeritus
Division of Orthopaedic Oncology
Rothman Institute
Director of Orthopaedic Oncology
Bone and Sarcoma Oncology
Fox Chase Cancer Center at Temple University Hospital
Philadelphia, PA
Disclosure Statement:
Consultant: Daiichi Sanko, Inc; OsteoCentric Technologies
Shareholder: Rothman Institute
Kristin M. Strogus, PA-C
Physician Assistant
Department of Surgical Oncology
Fox Chase Cancer Center
Philadelphia, PA
Disclosure Statement:
No relevant financial relationships with any commercial interests.
William D. Tap, MD
Chief Medical Oncologist
Sarcoma Medical Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure Statement:
Advisor or Consultant: Adaptimmune Therapeutics PLC; Agios Pharmaceuticals Inc; Blueprint Medicines; Daiichi Sankyo, Inc; Eisai Inc; Eli Lilly and Co; EMD Serono, Inc; GlaxoSmithKline PLC; Immune Design Corp; Janssen Pharmaceuticals Inc; Loxo Oncology Inc; NanoCarrier Co Ltd; Novartis Pharmaceuticals Corp; Plexxikon Inc
Intellectual Property/Patents: Companion Diagnostics for CDK4 Inhibitors
Officer/Board Member: Association for Clinical Oncology; Osteosarcoma Institute; Sarcoma Foundation of America
Shareholder: Atropos Therapeutics; Certis Oncology Solutions
EDUCATIONAL PLANNING COMMITTEE
American Academy of CME, Inc.
John Juchniewicz, MCIS, CHCP, Natalie Kirkwood, RN, BSN, JD: No relevant financial relationships with any commercial interests.
Spire Learning
Ashton Beggs, PharmD, BCACP, Allison Goldberg, and Lisa Colombo: No relevant financial relationships with any commercial interests.
Patient
Patient Planner: No relevant financial relationships with any commercial interests.
Reviewer
Theresa Pazionis, MD: No relevant financial relationships with any commercial interests.
OFF-LABEL STATEMENT
This educational activity will contain discussion of published and/or investigational uses of therapies that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants are encouraged to consult appropriate resources for any product or device mentioned in this program.
DISCLAIMER
The opinions expressed in this educational activity are those of the faculty and do not represent those of the Academy or Spire Learning. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.
PRIVACY STATEMENT
Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC to continuously improve the learning experience.
Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.
COPYRIGHT STATEMENTCopyright © 2020 by Spire Learning, LLC, and its Licensors. All rights reserved. No part of this publication or activity may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC. Spire Learning, LLC, and American Academy of CME, Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or activity, including any claims related to the products, drugs, or services mentioned herein.
